According to a new review of recently concluded studies comparing inhaled corticosteroids and the medicine cromolyn, asthmatic patients, including children and adults, can exercise a better control over their asthma and breathe deeper with inhaled corticosteroids.

James Guevara, M.D., of the University of Pennsylvania School of Medicine and colleagues said that asthmatic patients treated with steroids have an advantage of scoring higher in lung function tests. It was also remarked by them that the usage of corticosteroids allow patients to make lesser use of inhalers than patients who makes use of cromolyn.

From News-Medical.Net:

“To our knowledge, this is the first systematic review comparing the effects of cromolyn to the gold standard, inhaled steroids,” Guevara said.

The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

The consensus still leaves room for cromolyn treatment, according to William Storms, M.D., an allergist at the University of Colorado Health Sciences Center and director of the William Storms Allergy Clinic in Colorado Springs.

“Any expert would agree that inhaled corticosteroids are preferred first-line therapy for treatment of persistent asthma, which requires daily therapy. But we also will agree with the NIH [National Institutes of Health] asthma guidelines, which state that cromolyn and other drugs are alternative therapies,” Storms said.

Cromolyn, or sodium cromoglycate, and inhaled corticosteroids both block the action of certain inflammatory cells in the lungs. Physicians recommend both types of medication for persistent asthma, but individual studies disagree about which type of medication works best, the reviewers found.

Guevara and colleagues said that inhaled corticosteroids are superior to cromolyn irrespective of asthma severity level and also said that the attained results are so decisive that there is no need for any future study on this matter.

As per a recently concluded study, inhaled corticosteroids are more effective than sodium cromoglycate for treating asthma along with helping a lending hand to the lung to function in a normal way.

The study remarked that the superiority of inhaled corticosteroids tends to increase with its moderate low doses, compared to its low doses, as per Dr James Guevara, Department of Pediatrics at the University Of Pennsylvania School Of Medicine in Philadelphia and lead review author of this study.

From News.Bio-Medicine.org:

Inhaled corticosteroids (ICS) and sodium cromoglycate (SCG) are both used to help people with asthma. SCG is believed to have a low risk of causing long-term side effects, but despite anxieties relating to routine use of steroids, the use of ICS has steadily increased since the 1990s.

While they are both known to work, there has previously been a debate as to whether one is superior to the other.

By pooling data from randomized controlled trials that directly compared the effects of ICS and SCG the Cochrane Review Authors could assess the relative benefits of each. They considered measures of lung function, asthma control and the use of general healthcare services such as GPs and hospitals.

Their conclusion was that ICS controls asthma better than SCG and that it also leads to improved lung function. They were, however, unable to decide whether there were differences in side-effects as most of the trials ran for too short a time to assess long-term outcomes.

“The superiority of ICS over SCG appears to increase when patients use moderate doses of ICS, compared with when low doses of ICS are used,” says lead Review Author Dr James Guevara, who works in the department of Pediatrics at the University of Pennsylvania School of Medicine in Philadelphia.

Inhaled Corticosteroids have the ability to control asthma in a better manner than sodium cromoglycate and seems to be a better option for patients with asthma, DR Guevara concluded.

The study is believed to benefit almost more than one million asthma patients in the United States alone. This study has been accepted by the medical fraternity as a new ray of hope for future treatment developments in asthma management.